4CPS-035 Effectiveness and safety of monoclonal antibody pcsk9 inhibitors

BACKGROUND: Monoclonal antibody PCSK9-Inhibitors (PCSK9i), alirocumab and evolocumab, are a new class of drugs used to decrease LDL cholesterol (LDLc) and can be an option for patients with heterozygous familial hypercholesterolaemia (HeFH) and cardiovascular diseases (CVD) with high levels of LDLc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Martin, V Merino, Ortega-Garcia, MP, Blasco-Segura, P, Garcia, J Sanfeliu, Carrasco, A Lopez, Cristobal, R del Rio San, Guasp, I Toledo
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 4: Clinical pharmacy services
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535419/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.126
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados